Skip to main content
Clinical Trials/NCT02947217
NCT02947217
Enrolling By Invitation
Phase 4

A Randomized Controlled Trial of the Effect of Influenza Vaccination on Implantation and Pregnancy Rates After In-Vitro Fertilization

Center for Human Reproduction1 site in 1 country238 target enrollmentJanuary 19, 2017
ConditionsInfertility

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Infertility
Sponsor
Center for Human Reproduction
Enrollment
238
Locations
1
Primary Endpoint
Clinical Pregnancy
Status
Enrolling By Invitation
Last Updated
4 years ago

Overview

Brief Summary

In this study the investigators propose a randomized controlled trial to evaluate the effect of influenza vaccination on clinical pregnancy rates among women undergoing in vitro fertilization.

Detailed Description

Since 2004 flu vaccination has been recommended by American College of Obstetricians and Gynecologists (ACOG) Advisory Committee on Immunization Practices (ACIP) for all pregnant women during flu season, regardless of the trimester of pregnancy. Many studies have examined the safety of influenza vaccination and found benefits beyond the simple prevention of maternal infection including the reduction of still birth. Recently evidence has emerged that women who have received a flu vaccination were less likely to experience premature labor. The investigators hypothesize that some of the maternal benefits of influenza vaccination might be based on other than prevention of the flu, possibly secondary to the induction of immune system pathways that favor immunological tolerance. Induction of immune system pathways that favor immunological tolerance has long been considered a possible path to improved embryo implantation and reduce miscarriages, though the topic is still somewhat controversial. Patients undergoing IVF will be randomized in two strata: 1. History of recurrent miscarriage or implantation failure 2. No history of recurrent miscarriage of implantation failure Consenting patients will be randomized to receive either influenza vaccine or a saline placebo. Vaccination will occur 10 days before initiating anticipated menses or fertility treatment cycle start. All patients will be receiving an offered a second injection at the time of negative pregnancy test or at the time of sign-out with a clinical pregnancy. The second injection will either be placebo or influenza vaccination depending on the original randomization. Patients and clinical staff will remain blinded to the original treatment assignment, except for the study coordinator and the single staff member assigned to administer the injection.

Registry
clinicaltrials.gov
Start Date
January 19, 2017
End Date
December 31, 2024
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • All women preparing to undergo an IVF cycle
  • Women will only be allowed to participate in one treatment cycle
  • Willingness to have an influenza vaccination
  • Signed informed consent

Exclusion Criteria

  • Any contraindication for flu vaccination
  • Unwillingness to have a flu vaccination
  • Unwillingness to sign informed consent
  • Previous diagnosis of unfavorable endometrial development
  • Unresolved uterine condition that significantly compromises the endometrial cavity

Outcomes

Primary Outcomes

Clinical Pregnancy

Time Frame: 8 weeks

Intrauterine pregnancy with positive evidence of fetal heart beat

Secondary Outcomes

  • Implantation Rate(8 weeks)
  • Evidence of immune activation(14 to 21 days (at time of egg retrieval))

Study Sites (1)

Loading locations...

Similar Trials